Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 23, Issue 3
  5. Article
Volume 23, Issue 3
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

Background

The associations between Multiple Sclerosis (MS) and cardiovascular diseases, drawn from epidemiological studies, have attracted much attention in recent years.

Materials and Methods

The present study employed a monocentric, observational, retrospective cohort design. The primary objective of the study was to describe the Framingham Risk Score (FRS) rate in a cross-sectional analysis of our cohort of relapsing-remitting MS patients who are regularly followed up and, if applicable, to identify any association with the patient's Patient Determined Disease Steps (PDDS). Cardiovascular risk was classified as follows: low if the FRS is less than 10%, moderate if it is 10% to 19%, and high if it is 20% or higher.

Results

A total cohort of 229 patients was enrolled. The sample consists of 163 women (71.2%). FRS categories were distributed as follows: 97 (42.3%) patients had low FRS, 84 (36.7%) patients had moderate FRS, and 48 (21%) patients had high FRS. In the univariable ordinal regression analysis, one one-point increase in the PDDS scale was associated with a 24% risk of high FRS (. low) (proportional odds ratio [OR]=2.426, 95% confidence interval [CI] 1.660-3.545; <.0001). The results were also confirmed by the EDSS score, with a point increase in the EDSS score associated with a 19% risk of high FRS (. low) (proportional OR=1.953, 95% CI 1.429-2.669-1.04; <.0001).

Conclusion

The FRS demonstrated an association with the patient's “perception of the disease” as indicated by the PDDS. Further studies with larger cohorts are needed to adequately address cardiovascular risk in life-threatening conditions, such as MS.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X22666240815120018
2024-08-15
2025-01-29

  • From This Site

    /content/journals/cn/10.2174/1570159X22666240815120018
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. McGinleyM.P. GoldschmidtC.H. Rae-GrantA.D. Diagnosis and treatment of multiple sclerosis.JAMA2021325876577910.1001/jama.2020.26858 33620411
     [Google Scholar]
  2. ReichD.S. LucchinettiC.F. CalabresiP.A. Multiple Sclerosis.N. Engl. J. Med.2018378216918010.1056/NEJMra1401483 29320652
     [Google Scholar]
  3. MaricG. PekmezovicT. TamasO. VeselinovicN. JovanovicA. LalicK. MesarosS. DrulovicJ. Impact of comorbidities on the disability progression in multiple sclerosis.Acta Neurol. Scand.20221451242910.1111/ane.13516 34414566
     [Google Scholar]
  4. TetteyP. SimpsonS.Jr TaylorB.V. van der MeiI.A.F. Vascular comorbidities in the onset and progression of multiple sclerosis.J. Neurol. Sci.20143471-2233310.1016/j.jns.2014.10.020 25454639
     [Google Scholar]
  5. RappD. MichelsS. SchöpeJ. SchwingshacklL. TumaniH. SenelM. Associations between multiple sclerosis and incidence of heart diseases: Systematic review and meta-analysis of observational studies.Mult. Scler. Relat. Disord.20215610327910.1016/j.msard.2021.103279 34649134
     [Google Scholar]
  6. MarrieR.A. RudickR. HorwitzR. CutterG. TyryT. CampagnoloD. VollmerT. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.Neurology201074131041104710.1212/WNL.0b013e3181d6b125 20350978
     [Google Scholar]
  7. GiovannoniG. ButzkuevenH. Dhib-JalbutS. HobartJ. KobeltG. PepperG. SormaniM.P. ThalheimC. TraboulseeA. VollmerT. Brain health: time matters in multiple sclerosis.Mult. Scler. Relat. Disord.20169Suppl. 1S5S4810.1016/j.msard.2016.07.003 27640924
     [Google Scholar]
  8. YangF. HuT. HeK. YingJ. CuiH. Multiple sclerosis and the risk of cardiovascular diseases: A mendelian randomization study.Front. Immunol.20221386188510.3389/fimmu.2022.861885 35371017
     [Google Scholar]
  9. PattiF. LeoneC. D’AmicoE. Treatment options of cognitive impairment in multiple sclerosis.Neurol. Sci.201031Suppl. 2S265S26910.1007/s10072‑010‑0438‑7 20953811
     [Google Scholar]
  10. MocciaM. LanzilloR. PalladinoR. ManiscalcoG.T. De RosaA. RussoC. MassarelliM. CarotenutoA. PostiglioneE. CaporaleO. TriassiM. BresciaM.V. The Framingham cardiovascular risk score in multiple sclerosis.Eur. J. Neurol.20152281176118310.1111/ene.12720 25912468
     [Google Scholar]
  11. Davey SmithG. HemaniG. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies.Hum. Mol. Genet.201423R1R89R9810.1093/hmg/ddu328 25064373
     [Google Scholar]
  12. LawlorD.A. HarbordR.M. SterneJ.A.C. TimpsonN. Davey SmithG. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology.Stat. Med.20082781133116310.1002/sim.3034 17886233
     [Google Scholar]
  13. JahangiryL. FarhangiM.A. RezaeiF. Framingham risk score for estimation of 10-years of cardiovascular diseases risk in patients with metabolic syndrome.J. Health Popul. Nutr.20173613610.1186/s41043‑017‑0114‑0 29132438
     [Google Scholar]
  14. MarrieR.A. PatelR. FigleyC.R. KornelsenJ. BoltonJ.M. GraffL.A. MazerolleE.L. HelmickC. O’GradyC. UddinM.N. MarriottJ.J. BernsteinC.N. FiskJ.D. Higher framingham risk scores are associated with greater loss of brain volume over time in multiple sclerosis.Mult. Scler. Relat. Disord.20215410308810.1016/j.msard.2021.103088 34186319
     [Google Scholar]
  15. ZanghìA. D’AmicoE. FermoS.L. PattiF. Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: A cohort ambispective single-centre study.Ther. Adv. Chronic Dis.202112204062232098312110.1177/2040622320983121 33717425
     [Google Scholar]
  16. BallendineS. PoliakovI.P. P.029 Assessing disability in MS during the COVID-19 pandemic: correlation between PDDS and EDSS scores obtained before and after virtual assessments.Can. J. Neurol. Sci.202249S1S15
     [Google Scholar]
  17. LearmonthY.C. MotlR.W. SandroffB.M. PulaJ.H. CadavidD. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis.BMC Neurol.20131313710.1186/1471‑2377‑13‑37 23617555
     [Google Scholar]
  18. LavorgnaL. MieleG. PetruzzoM. LanzilloR. BonavitaS. Online validation of the Italian version of the patient determined disease steps scale (PDDS) in people with multiple sclerosis.Mult. Scler. Relat. Disord.20182110810910.1016/j.msard.2018.02.014 29547779
     [Google Scholar]
  19. HauerL. PerneczkyJ. SellnerJ. A global view of comorbidity in multiple sclerosis: A systematic review with a focus on regional differences, methodology, and clinical implications.J. Neurol.2021268114066407710.1007/s00415‑020‑10107‑y 32719975
     [Google Scholar]
  20. BezziniD. GualdaniE. RazzanelliM. BattagliaM.A. CorteseR. FrancesconiP. UlivelliM. Prevalence of chronic comorbidities in people with multiple sclerosis: descriptive study based on administrative data in Tuscany (Central Italy).Neurol. Sci.202243116407641410.1007/s10072‑022‑06345‑9 35978257
     [Google Scholar]
  21. ThompsonA.J. BanwellB.L. BarkhofF. CarrollW.M. CoetzeeT. ComiG. CorrealeJ. FazekasF. FilippiM. FreedmanM.S. FujiharaK. GalettaS.L. HartungH.P. KapposL. LublinF.D. MarrieR.A. MillerA.E. MillerD.H. MontalbanX. MowryE.M. SorensenP.S. TintoréM. TraboulseeA.L. TrojanoM. UitdehaagB.M.J. VukusicS. WaubantE. WeinshenkerB.G. ReingoldS.C. CohenJ.A. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol.201817216217310.1016/S1474‑4422(17)30470‑2 29275977
     [Google Scholar]
  22. KurtzkeJ.F. Rating neurologic impairment in multiple sclerosis.Neurology198333111444145210.1212/WNL.33.11.1444 6685237
     [Google Scholar]
  23. KisterI. ChamotE. SalterA.R. CutterG.R. BaconT.E. HerbertJ. Disability in multiple sclerosis.Neurology201380111018102410.1212/WNL.0b013e3182872855 23427319
     [Google Scholar]
  24. NicoleB. CarolineG. Vanessa DiF. AmberS. Severity of symptoms among persons with multiple sclerosis by PDDS score (P13-3.011).Neurology202310017Suppl. 23334
     [Google Scholar]
  25. D’AgostinoR.B.Sr VasanR.S. PencinaM.J. WolfP.A. CobainM. MassaroJ.M. KannelW.B. General cardiovascular risk profile for use in primary care: The Framingham Heart Study.Circulation2008117674375310.1161/CIRCULATIONAHA.107.699579 18212285
     [Google Scholar]
  26. MincuR.I. MagdaL.S. FlorescuM. VelceaA. MihailaS. MihalceaD. PopescuB.O. ChiruA. TiuC. CintezaM. VinereanuD. Cardiovascular dysfunction in multiple sclerosis.Maedica 2015104364370 28465741
     [Google Scholar]
  27. PetruzzoM. ReiaA. ManiscalcoG.T. LuisoF. LanzilloR. RussoC.V. CarotenutoA. AllegoricoL. PalladinoR. Brescia MorraV. MocciaM. The Framingham cardiovascular risk score and 5‐year progression of multiple sclerosis.Eur. J. Neurol.202128389390010.1111/ene.14608 33091222
     [Google Scholar]
  28. JepsenP. JohnsenS.P. GillmanM.W. SørensenH.T. Interpretation of observational studies.Heart200490895696010.1136/hrt.2003.017269 15253985
     [Google Scholar]
/content/journals/cn/10.2174/1570159X22666240815120018
Loading
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience
Curr. Neuropharmacol. 23, 310 (2025); https://doi.org/10.2174/1570159X22666240815120018
/content/journals/cn/10.2174/1570159X22666240815120018
/content/journals/cn/10.2174/1570159X22666240815120018
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): cardiovascular diseases; disability; Framingham risk score; monocentric experience; multiple sclerosis; patient determined disease steps

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test